General Information of Drug (ID: DM62XC3)

Drug Name
4,6-Dichloro-1H-indole-2-carboxylic acid Drug Info
Synonyms
101861-63-6; 4,6-dichloro-1H-indole-2-carboxylic acid; 4,6-Dichloroindole-2-carboxylic acid; CHEMBL301556; 1H-Indole-2-carboxylicacid, 4,6-dichloro-; 3-(4,6-Dichloro-2-carboxyindol-3-yl)propionic acid; 3-Dccip; KBio2_007460; PubChem7197; Spectrum_001822; SpecPlus_000800; 4,6-Dichloro-1H-indole-2-carboxylicacid; ACMC-1BPUR; AC1Q3MQM; AC1L2SZE; Maybridge1_006804; AC1Q73TA; Oprea1_268024; KBioSS_002327; SCHEMBL727389; DivK1c_006896; KBio2_004892; KBio2_002324; KBio1_001840; CTK0H4782; HMS560N06; DTXSID80144299; MolPort-000-147-351; Mdl-29951
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1] , [2]
Cross-matching ID
PubChem CID
127988
CAS Number
CAS 101861-63-6
TTD Drug ID
DM62XC3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glycine DMIOZ29 Malnutrition 5B50-5B71 Approved [3]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [4]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [5]
Spermine DMD4BFY N. A. N. A. Terminated [6]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [7]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [8]
Dizocilpine DMMGYXR Cerebrovascular ischaemia 8B1Z Terminated [9]
RPR-104632 DM9L50N N. A. N. A. Terminated [10]
L-698532 DMO9HM7 Neurological disorder 6B60 Terminated [11]
L-695902 DMT1DNS N. A. N. A. Terminated [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cycloserine DMT1I52 Bacterial infection 1A00-1C4Z Approved [12]
D-Serine DM3YH4I N. A. N. A. Phase 4 [13]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [14]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [4]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [5]
Spermine DMD4BFY N. A. N. A. Terminated [6]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [15]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [8]
Dizocilpine DMMGYXR Cerebrovascular ischaemia 8B1Z Terminated [9]
RPR-104632 DM9L50N N. A. N. A. Terminated [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha 1-PI DMXC1K9 Alpha-1 antitrypsin deficiency 5C5A Approved [16]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [14]
CP-101,606 DMIU19E Parkinson disease 8A00.0 Phase 2 [17]
CERC-301 DMSABRI Major depressive disorder 6A70.3 Phase 2 [18]
RGH-896 DMCHZAN Peripheral neuropathy 8C0Z Phase 2 [19]
MIJ821 DMN45RI Major depressive disorder 6A70.3 Phase 2 [20]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [4]
Neu-2000 DMNJTLC Cardiac arrest MC82 Phase 1 [21]
EVT100 DMAKWQD Major depressive disorder 6A70.3 Phase 1 [22]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [5]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Managlinat dialanetil DMBYDNE Type-2 diabetes 5A11 Phase 2 [23]
MB07803 DMHU8SJ Type-2 diabetes 5A11 Phase 2 [24]
4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ Discovery agent N.A. Investigative [25]
Fructose-6-phosphate DMU5SAF Discovery agent N.A. Investigative [12]
1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea DM4G0NH Discovery agent N.A. Investigative [26]
2,5-Anhydroglucitol-1,6-Biphosphate DMLDHMB Discovery agent N.A. Investigative [12]
1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea DMIPAMW Discovery agent N.A. Investigative [26]
4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol DMA9TCD Discovery agent N.A. Investigative [25]
3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol DM8EH07 Discovery agent N.A. Investigative [25]
2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol DMOYT8I Discovery agent N.A. Investigative [25]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fructose-1,6-bisphosphatase (FBP) TTWHDVK F16P1_HUMAN; F16P2_HUMAN Inhibitor [1]
Glutamate receptor ionotropic NMDA 1 (NMDAR1) TTLD29N NMDZ1_HUMAN Inhibitor [2]
Glutamate receptor ionotropic NMDA 2A (NMDAR2A) TTKJEMQ NMDE1_HUMAN Inhibitor [2]
Glutamate receptor ionotropic NMDA 2B (NMDAR2B) TTN9D8E NMDE2_HUMAN Inhibitor [2]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
3 Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
4 Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
5 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
6 Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
8 Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
9 Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
10 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
11 Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
12 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
13 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
14 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
16 NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
17 NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
18 Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
19 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
20 Clinical pipeline report, company report or official report of Cadent Therapeutics.
21 Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
22 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23 MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5.
24 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
25 A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
26 Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12.